A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis

Inclusion Criteria:

• Adult patients, 18 to 65 years of age inclusive
• Patients with chronic kidney disease Stage III-IV not on dialysis
• Hb < 10 g/dL (for correction of anemia) or Hb 10-12 g/dL and receiving any other ESA (for maintenance of Hb levels)
• Adequate iron status as judged by the treating physician

Exclusion Criteria:

• Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication
• Significant acute or chronic bleeding
• Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)
• Active malignant disease during the last five years (except non-melanoma skin cancer)
• Uncontrolled or symptomatic secondary hyperparathyroidism
• Epileptic seizure during the last 6 months
• Poorly controlled hypertension (sitting blood pressure > 170/100 mmHG)
• Myocardial infarction or stroke, or severe or unstable CAD
• Severe liver disease during the previous 6 months
• Congestive heart failure NYHA Class III-IV
• Diagnosis or suspicion of pure red cell aplasia (PRCA)
• Planned elective surgery during the study period (except cataract surgery and vascular access surgery)
• Transfusion of red blood cells during the previous 2 months
• Pregnant women
• Any contra-indications to Mircera